Bayer AG (BAYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 174

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Bayer AG, Medical Devices Deals, 2011 to YTD 2017 13
Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Bayer AG, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 19
Venture Financing 21
BlueRock Therapeutics Raises USD225 Million in Series A Financing 21
Private Equity 22
Bayer May Sell Dermatology Business 22
Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 23
Partnerships 24
ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 24
Bayer and PeptiDream Enter into Partnership 25
Bayer Enters into Co-Development Agreement with Loxo Oncology 26
Bayer and Vanderbilt University Medical Center Enter into Research Agreement 27
leadXpro Enters into Agreement with Bayer 28
University of Pittsburgh and Bayer Form Research Collaboration Agreement 29
Bayer Enters into Partnership with Evotec 30
Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 31
Bayer Enters into Co-Development Agreement with Regeneron Pharma 32
Bayer and CRISPR Therapeutics Forms Joint Venture 33
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 34
Proteros Biostructures Enters into Research Agreement with Bayer 35
Bayer HealthCare Enters Co-Development Agreement with University of Oxford 36
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 37
arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 38
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 39
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 40
Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 41
Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 42
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 43
X-Chem and Bayer Pharma Expand Agreement 44
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 45
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 46
Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 48
Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 49
Bayer HealthCare Pharma Enters Into Research Agreement With Ludwig Boltzmann Institute 50
MediSapiens Enters Into Co-Development Agreement With Bayer HealthCare Pharma 51
Bayer Enters Into Joint Venture Agreement With Yunona Holdings 52
Dong-A Pharma Enters Into Co-Marketing Agreement With Bayer Korea 53
Bayer Schering Pharma Enters Into Research Agreement With University of California, San Francisco 54
Licensing Agreements 55
Bayer Enters into Licensing Agreement with Progenics Pharma 55
Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 56
Bayer Enters into Licensing Agreement with ERS Genomics 57
X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58
Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 59
BioInvent Extends Licensing Agreement With Bayer Pharma 60
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 61
Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 62
Lead Discovery Enters Into Licensing Agreement With Bayer Schering 63
Equity Offering 64
Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 64
Debt Offering 65
Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 65
Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 66
Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 67
Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 68
Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 69
Bayer Raises USD500 Million in Public Offering of Notes Due 2016 70
Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 71
Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 72
Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 73
Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 74
Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 76
Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 78
Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 79
Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 80
Bayer Completes Public Offering Of Notes Due 2019 For US$102 Million 81
Bayer Completes Public Offering Of Notes Due 2016 For US$259 Million 82
Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For US$363 Million 83
Asset Transactions 84
Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 84
WellSpring Pharma Acquires Bactine 85
Alvogen Acquires Five Hormonal Products from Bayer Pharma 86
Bayer Korea to Sell Mercilon 87
Alliance Pharma Acquires Rights To Irenat From Bayer 88
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 89
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 90
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 91
Acquisition 92
Bayer to Acquire Monsanto for USD66 Billion 92
Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 94
Bayer Acquires Dihon Pharma for USD586 Million 95
Bayer Nordic Completes Acquisition Of Algeta For US$2.58 Billion 96
Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 98
Bayer Completes Acquisition Of 96.4% Stake In Conceptus For US$1.1 Billion 99
Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 101
Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 102
SuperGen Completes Acquisition Of Astex Therapeutics 103
Bayer AG - Key Competitors 106
Bayer AG - Key Employees 107
Bayer AG - Locations And Subsidiaries 110
Head Office 110
Other Locations & Subsidiaries 110
Joint Venture 118
Recent Developments 120
Strategy And Business Planning 120
Sep 20, 2016: Bayer sets ambitious growth and earnings aspirations 120
Financial Announcements 122
Oct 26, 2017: Bayer: Sales and earnings increased 122
Apr 27, 2017: Strong start to the year for Bayer 127
Apr 26, 2016: Bayer Announces Interim report for the first quarter of 2016 130
Corporate Communications 132
Nov 15, 2017: Heiko Schipper is the new CEO and Head of the Consumer Health Division at Bayer 132
Sep 29, 2017: Bayer helping people affected by the earthquake in Mexico 133
Sep 12, 2017: Wolfgang Nickl to be new Chief Financial Officer at Bayer 134
Apr 27, 2017: Supervisory Board of Bayer extends service contract of CFO Johannes Dietsch to the end of May 2018 135
Jan 17, 2017: Dr. Carsten Brunn to Lead Bayer's Pharmaceuticals Business in the Americas Region 136
Oct 17, 2016: Bayer Early Excellence in Science Award 2016: EUR 30,000 for international research scientists 137
Apr 25, 2016: 2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner 139
Feb 24, 2016: Werner Baumann to succeed Dr. Marijn Dekkers as Chairman of the Board of Management of Bayer AG 140
Legal and Regulatory 141
Aug 22, 2017: Bayer will continue to work constructively with the European Commission 141
Government and Public Interest 142
Jul 11, 2017: Bayer Awards $2 Million in Grants to Advance Hemophilia Research and Patient Care 142
Feb 22, 2017: Another record year for Bayer - good progress with the acquisition of Monsanto 143
Nov 13, 2016: New landmark study reveals adults with diabetes at unnecessary risk of vision loss 147
May 12, 2016: Bayer: B vitamins - an effective team for mood and brain activity 149
Feb 25, 2016: Another record year for Bayer 150
Product News 153
Aug 10, 2016: Bayer: Prevalence of life-threatening neural tube defects on the rise 153
07/21/2016: Sorafenib treatment alters immunosuppressive phenotypes in hepatocellular carcinoma 154
02/03/2016: NICE issues full guidance for Xofigoq (radium-223 dichloride) 155
01/27/2016: NICE recommends radium 223 dichloride for prostate cancer 156
01/04/2016: Bayer Presents Latest Xofigo (radium Ra 223 dichloride) Injection Research at ASCO GU 2016 157
Product Approvals 158
Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan 158
Clinical Trials 159
Jul 24, 2017: Evotec and Bayer Advance Endometriosis Programme into Phase I Clinical Development and Extend Alliance 159
Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 160
Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 161
May 19, 2016: Bayer to Showcase Anetumab Ravtansine at ASCO 2016 162
May 19, 2016: Bayer to Showcase Latest data on Nexavar (sorafenib) at ASCO 2016 163
May 18, 2016: Bayer to Showcase Latest Data on Xofigo (radium Ra 223 dichloride) at ASCO 2016 164
Mar 07, 2016: Major Liver Cancer Study Completes Palliative Cohort Enrolment 166
Jan 26, 2016: ImmunoGen Earns Milestone with Bayer's Initiation of a Phase 2 Clinical Study Designed to Support Anetumab Ravtansine Registration 167
Other Significant Developments 168
Dec 01, 2017: Bayer invests in differentiated drug pipeline with over 50 projects focused on high unmet medical needs 168
Jul 27, 2016: Bayer raises sales and earnings 171
Appendix 174
Methodology 174
About GlobalData 174
Contact Us 174
Disclaimer 174

List of Tables
Bayer AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Bayer AG, Deals By Therapy Area, 2011 to YTD 2017 11
Bayer AG, Medical Devices Deals, 2011 to YTD 2017 13
Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 19
BlueRock Therapeutics Raises USD225 Million in Series A Financing 21
Bayer May Sell Dermatology Business 22
Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 23
ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 24
Bayer and PeptiDream Enter into Partnership 25
Bayer Enters into Co-Development Agreement with Loxo Oncology 26
Bayer and Vanderbilt University Medical Center Enter into Research Agreement 27
leadXpro Enters into Agreement with Bayer 28
University of Pittsburgh and Bayer Form Research Collaboration Agreement 29
Bayer Enters into Partnership with Evotec 30
Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 31
Bayer Enters into Co-Development Agreement with Regeneron Pharma 32
Bayer and CRISPR Therapeutics Forms Joint Venture 33
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 34
Proteros Biostructures Enters into Research Agreement with Bayer 35
Bayer HealthCare Enters Co-Development Agreement with University of Oxford 36
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 37
arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 38
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 39
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 40
Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 41
Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 42
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 43
X-Chem and Bayer Pharma Expand Agreement 44
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 45
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 46
Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 48
Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 49
Bayer HealthCare Pharma Enters Into Research Agreement With Ludwig Boltzmann Institute 50
MediSapiens Enters Into Co-Development Agreement With Bayer HealthCare Pharma 51
Bayer Enters Into Joint Venture Agreement With Yunona Holdings 52
Dong-A Pharma Enters Into Co-Marketing Agreement With Bayer Korea 53
Bayer Schering Pharma Enters Into Research Agreement With University of California, San Francisco 54
Bayer Enters into Licensing Agreement with Progenics Pharma 55
Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 56
Bayer Enters into Licensing Agreement with ERS Genomics 57
X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58
Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 59
BioInvent Extends Licensing Agreement With Bayer Pharma 60
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 61
Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 62
Lead Discovery Enters Into Licensing Agreement With Bayer Schering 63
Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 64
Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 65
Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 66
Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 67
Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 68
Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 69
Bayer Raises USD500 Million in Public Offering of Notes Due 2016 70
Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 71
Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 72
Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 73
Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 74
Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 76
Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 78
Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 79
Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 80
Bayer Completes Public Offering Of Notes Due 2019 For US$102 Million 81
Bayer Completes Public Offering Of Notes Due 2016 For US$259 Million 82
Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For US$363 Million 83
Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 84
WellSpring Pharma Acquires Bactine 85
Alvogen Acquires Five Hormonal Products from Bayer Pharma 86
Bayer Korea to Sell Mercilon 87
Alliance Pharma Acquires Rights To Irenat From Bayer 88
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 89
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 90
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 91
Bayer to Acquire Monsanto for USD66 Billion 92
Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 94
Bayer Acquires Dihon Pharma for USD586 Million 95
Bayer Nordic Completes Acquisition Of Algeta For US$2.58 Billion 96
Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 98
Bayer Completes Acquisition Of 96.4% Stake In Conceptus For US$1.1 Billion 99
Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 101
Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 102
SuperGen Completes Acquisition Of Astex Therapeutics 103
Bayer AG, Key Competitors 106
Bayer AG, Key Employees 107
Bayer AG, Subsidiaries 110
Bayer AG, Joint Venture 118

List of Figures
Bayer AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Bayer AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Bayer AG, Medical Devices Deals, 2011 to YTD 2017 13

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Bayer AG (BAYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027